Clinical trials: Tirzepatide
Tirzepatide, Frozen Embryo Transfer
Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer
To evaluate the efficacy and safety of Dual GIP/GLP-1 receptor agonist pretreatment on reproductive outcomes in obese women before frozen embryo transfer.
- Conditions
- Tirzepatide, Frozen Embryo Transfer, Obesity
- Trial name
- NCT07811895
- Testing
- Dual GIP/GLP-1 receptor agonist
- Where
- China
- Volunteers
- 1,510 people
- Sponsor
- RenJi Hospital
Drug Discontinuation, Substance Use Disorders
Clinical and Neurobehavioral Changes With Weight Loss Drug Discontinuation and Reinitiation
The goal of this clinical study with research procedures is to learn how stopping and restarting tirzepatide (a medication that helps regulate blood sugar and appetite) affects brain activity, behavior, and health in adults ages…
- Conditions
- Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
- Trial name
- CLIN-GLP1 (NCT07387796)
- Testing
- Discontinuation and Reinitiation of Tirzepatide
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The University of Texas at Dallas
Heart Failure and Reduced Ejection Fraction, Obesity & Overweight
Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity
The goal of this clinical trial is to learn if tirzepatide works to improve physical function in adults with heart failure and obesity. It will also learn about the safety of tirzepatide.
- Conditions
- Heart Failure and Reduced Ejection Fraction, Obesity & Overweight, Tirzepatide
- Trial name
- DUAL-HFrEF (NCT07738276)
- Testing
- Tirzepatide
- Volunteers
- 60 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF)
Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF
This multicenter, randomized, open-label, blinded-endpoint trial evaluates whether weekly subcutaneous tirzepatide for 12 months reduces atrial fibrillation (AF) recurrence after catheter ablation in adults with obesity and heart…
- Conditions
- Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFpEF), Tirzepatide
- Trial name
- TEAR-AF-HFpEF (NCT07630454)
- Testing
- Tirzepatide, Structured Lifestyle Intervention
- Where
- China
- Volunteers
- 602 people
- Sponsor
- Yunlong Wang
Tirzepatide
Tirzepatide (Spartina) in Obese Kidney Transplant Recipients
Post-transplant obesity is a common complication after kidney transplantation, largely attributed to recovery from uremia, increased appetite, sedentary lifestyle, and long-term corticosteroid exposure.
- Trial name
- NCT07423247
- Testing
- Tirzepatide
- Where
- Iran
- Volunteers
- 30 people
- Sponsor
- Shahid Beheshti University of Medical Sciences